We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$156M
Cap. Flow %
-39.58%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 5.44%
3 Communication Services 2.79%
4 Industrials 1.83%
5 Consumer Discretionary 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMMT icon
76
Summit Therapeutics
SMMT
$10.4B
$1.26M 0.32%
147,450
-50,000
-25% -$534K
SIOX
77
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.24M 0.31%
+12,500
New +$1.32M
SNDX icon
78
Syndax Pharmaceuticals
SNDX
$1.69B
$1.19M 0.3%
166,310
– –
PVLA
79
Palvella Therapeutics
PVLA
$1.99B
$1.13M 0.29%
10,125
– –
MA icon
80
Mastercard
MA
$506B
$1.12M 0.28%
+10,825
New +$1.12M
MYOK
81
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.08M 0.27%
83,240
– –
PRQR icon
82
ProQR Therapeutics
PRQR
$243M
$980K 0.25%
+200,000
New +$1.03M
VTVT icon
83
vTv Therapeutics
VTVT
$127M
$966K 0.24%
5,000
– –
RARX
84
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$911K 0.23%
+60,000
New +$816K
TMO icon
85
Thermo Fisher Scientific
TMO
$213B
$898K 0.23%
+6,363
New +$938K
LJPC
86
DELISTED
La Jolla Pharmaceutical Company
LJPC
$888K 0.22%
+50,677
New +$971K
PANW icon
87
Palo Alto Networks
PANW
$270B
$882K 0.22%
42,312
– –
TBT icon
88
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$304M
$761K 0.19%
+18,650
New +$704K
IMDZ
89
DELISTED
Immune Design Corp.
IMDZ
$567K 0.14%
103,000
-100,000
-49% -$706K
OTLK icon
90
Outlook Therapeutics
OTLK
$183M
$525K 0.13%
1,090
-160
-13% -$89.6K
VIRX
91
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$453K 0.11%
+3,571
New +$497K
MRTX
92
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$383K 0.1%
80,528
-69,472
-46% -$378K
SEDG icon
93
SolarEdge
SEDG
$2.51B
$325K 0.08%
+26,203
New +$364K
CABO icon
94
Cable One
CABO
$227M
$311K 0.08%
500
+130
+35% +$77.2K
SITE icon
95
SiteOne Landscape Supply
SITE
$4.12B
$306K 0.08%
8,820
+800
+10% +$26.8K
HZNP
96
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$293K 0.07%
+18,100
New +$328K
UNH icon
97
UnitedHealth
UNH
$376B
$272K 0.07%
1,700
– –
MHK icon
98
Mohawk Industries
MHK
$7.5B
$220K 0.06%
1,100
– –
LOW icon
99
Lowe's Companies
LOW
$117B
$185K 0.05%
2,600
-340
-12% -$24.1K
SEE
100
DELISTED
Sealed Air
SEE
$159K 0.04%
+3,500
New +$161K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $156M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.